Cargando…
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
Very rapid progression of disease with a median survival of 6-9 months is a common feature of metastatic cutaneous malignant melanoma. Nevertheless, substantial variability of survival suggests that metastatic cutaneous malignant melanoma can be divided into several biological subgroups. Pretreatmen...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062938/ https://www.ncbi.nlm.nih.gov/pubmed/9662248 |
_version_ | 1782137233585733632 |
---|---|
author | Franzke, A. Probst-Kepper, M. Buer, J. Duensing, S. Hoffmann, R. Wittke, F. Volkenandt, M. Ganser, A. Atzpodien, J. |
author_facet | Franzke, A. Probst-Kepper, M. Buer, J. Duensing, S. Hoffmann, R. Wittke, F. Volkenandt, M. Ganser, A. Atzpodien, J. |
author_sort | Franzke, A. |
collection | PubMed |
description | Very rapid progression of disease with a median survival of 6-9 months is a common feature of metastatic cutaneous malignant melanoma. Nevertheless, substantial variability of survival suggests that metastatic cutaneous malignant melanoma can be divided into several biological subgroups. Pretreatment serum levels of soluble adhesion molecules and various clinical parameters in cutaneous metastatic malignant melanoma were evaluated to determine their prognostic value. In this study pretreatment serum levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular cell adhesion molecule 1 (sICAM-1), soluble endothelial leukocyte adhesion molecule 1 (sE-selectin) and multiple clinical factors were assessed in relation to overall survival of 97 consecutive patients with metastatic cutaneous malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, both univariate and multivariate Cox proportional-hazards models were used. Elevated pretreatment serum levels of sVCAM-1 (P < 0.005) and of lactate dehydrogenase (P < 0.002) were rendered statistically independent and were significantly associated with unfavourable outcome. Patients were assigned to one of three risk categories (low, intermediate and high) according to a cumulative risk score defined as the function of the sum of these two variables. There were significant differences in overall survival (P < 0.0001) between low- (n = 53, 5-year survival probability of 23.3%), intermediate- (n = 29, 5-year survival probability of 9.9%) and high-risk (n = 15) patients. Elevated pretreatment serum levels of sVCAM-1 and of lactate dehydrogenase correlate with poor outcome in metastatic cutaneous malignant melanoma. These data support risk stratification for future therapeutic trials and identify factors that need to be validated in prospective studies and may potentially influence decision-making in palliative management of patients with disseminated cutaneous malignant melanoma. |
format | Text |
id | pubmed-2062938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group|1 |
record_format | MEDLINE/PubMed |
spelling | pubmed-20629382009-09-10 Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Franzke, A. Probst-Kepper, M. Buer, J. Duensing, S. Hoffmann, R. Wittke, F. Volkenandt, M. Ganser, A. Atzpodien, J. Br J Cancer Research Article Very rapid progression of disease with a median survival of 6-9 months is a common feature of metastatic cutaneous malignant melanoma. Nevertheless, substantial variability of survival suggests that metastatic cutaneous malignant melanoma can be divided into several biological subgroups. Pretreatment serum levels of soluble adhesion molecules and various clinical parameters in cutaneous metastatic malignant melanoma were evaluated to determine their prognostic value. In this study pretreatment serum levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular cell adhesion molecule 1 (sICAM-1), soluble endothelial leukocyte adhesion molecule 1 (sE-selectin) and multiple clinical factors were assessed in relation to overall survival of 97 consecutive patients with metastatic cutaneous malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, both univariate and multivariate Cox proportional-hazards models were used. Elevated pretreatment serum levels of sVCAM-1 (P < 0.005) and of lactate dehydrogenase (P < 0.002) were rendered statistically independent and were significantly associated with unfavourable outcome. Patients were assigned to one of three risk categories (low, intermediate and high) according to a cumulative risk score defined as the function of the sum of these two variables. There were significant differences in overall survival (P < 0.0001) between low- (n = 53, 5-year survival probability of 23.3%), intermediate- (n = 29, 5-year survival probability of 9.9%) and high-risk (n = 15) patients. Elevated pretreatment serum levels of sVCAM-1 and of lactate dehydrogenase correlate with poor outcome in metastatic cutaneous malignant melanoma. These data support risk stratification for future therapeutic trials and identify factors that need to be validated in prospective studies and may potentially influence decision-making in palliative management of patients with disseminated cutaneous malignant melanoma. Nature Publishing Group|1 1998-07 /pmc/articles/PMC2062938/ /pubmed/9662248 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Franzke, A. Probst-Kepper, M. Buer, J. Duensing, S. Hoffmann, R. Wittke, F. Volkenandt, M. Ganser, A. Atzpodien, J. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. |
title | Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. |
title_full | Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. |
title_fullStr | Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. |
title_full_unstemmed | Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. |
title_short | Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. |
title_sort | elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062938/ https://www.ncbi.nlm.nih.gov/pubmed/9662248 |
work_keys_str_mv | AT franzkea elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT probstkepperm elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT buerj elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT duensings elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT hoffmannr elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT wittkef elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT volkenandtm elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT gansera elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma AT atzpodienj elevatedpretreatmentserumlevelsofsolublevascularcelladhesionmolecule1andlactatedehydrogenaseaspredictorsofsurvivalincutaneousmetastaticmalignantmelanoma |